cerivastatin and Myoglobinuria

cerivastatin has been researched along with Myoglobinuria* in 2 studies

Other Studies

2 other study(ies) available for cerivastatin and Myoglobinuria

Article	Year
Clearance rates of cerivastatin metabolites in a patient with cerivastatin-induced rhabdomyolysis. Journal of clinical pharmacy and therapeutics, 2005, Volume: 30, Issue:2 We report on a patient who developed acute rhabdomyolysis after taking cerivastatin. A 74-year-old hypercholestrerolaemic woman taking cerivastatin (0.15 mg/day) for 22 days complained of general muscle weakness and muscle pain. Her serum creatinine phosphokinase level was 19,190 IU/L. Serum myoglobin was over 3000 ng/mL. Serum concentration of cerivastatin at 6 h after taking the last dose (0.15 mg) was 8062.5 ng/L, which was almost 5.7 times higher than that of normal persons. The serum concentration of cerivastatin showed that the half-life of cerivastatin in this patient was 22.4 h, compared with 2.4 h for normal controls. Cerivastatin is catabolized by cytochrome P450, 3A4 and 2C8 to M-1, and by 2C8 to M-23. The ratio of M-23 to M-1 in her serum was much lower than that of control persons (0.64 vs. 2.08). She had previously taken simvastatin which is metabolized by CYP3A4, without any sign and symptoms of rhabdomyolysis. These results suggest that the slowed clearance of cerivastatin in this patient might have been compounded by cytochrome P450, 2C8 dysfunction. Topics: Acute Disease; Aged; Aryl Hydrocarbon Hydroxylases; Creatinine; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Administration Schedule; Female; Half-Life; Humans; Hypercholesterolemia; Metabolic Clearance Rate; Myoglobin; Myoglobinuria; Pyridines; Rhabdomyolysis; Simvastatin; Time Factors	2005
Myoglobinuria and COX deficiency in a patient taking cerivastatin and gemfibrozil. Neurology, 2003, Jan-14, Volume: 60, Issue:1 The authors describe a patient who presented with myoglobinuria after starting cerivastatin-gemfibrozil therapy. Muscle histochemistry revealed ragged-red fibers and cytochrome c oxidase negative (COX) fibers, and biochemistry showed a defect of COX activity. Immunoblot analysis showed a 60% reduction of COX I and COX II polypeptides. Cerivastatin myotoxicity might be related to a depletion of essential metabolites needed to anchor COX subunit I to mitochondrial membrane. Topics: Aged; Biopsy; Cytochrome-c Oxidase Deficiency; Female; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Muscle Fibers, Fast-Twitch; Muscle Weakness; Muscle, Skeletal; Myoglobinuria; Pain; Pyridines	2003

Article

Year

Clearance rates of cerivastatin metabolites in a patient with cerivastatin-induced rhabdomyolysis.

Journal of clinical pharmacy and therapeutics, 2005, Volume: 30, Issue:2

We report on a patient who developed acute rhabdomyolysis after taking cerivastatin. A 74-year-old hypercholestrerolaemic woman taking cerivastatin (0.15 mg/day) for 22 days complained of general muscle weakness and muscle pain. Her serum creatinine phosphokinase level was 19,190 IU/L. Serum myoglobin was over 3000 ng/mL. Serum concentration of cerivastatin at 6 h after taking the last dose (0.15 mg) was 8062.5 ng/L, which was almost 5.7 times higher than that of normal persons. The serum concentration of cerivastatin showed that the half-life of cerivastatin in this patient was 22.4 h, compared with 2.4 h for normal controls. Cerivastatin is catabolized by cytochrome P450, 3A4 and 2C8 to M-1, and by 2C8 to M-23. The ratio of M-23 to M-1 in her serum was much lower than that of control persons (0.64 vs. 2.08). She had previously taken simvastatin which is metabolized by CYP3A4, without any sign and symptoms of rhabdomyolysis. These results suggest that the slowed clearance of cerivastatin in this patient might have been compounded by cytochrome P450, 2C8 dysfunction.

Topics: Acute Disease; Aged; Aryl Hydrocarbon Hydroxylases; Creatinine; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Administration Schedule; Female; Half-Life; Humans; Hypercholesterolemia; Metabolic Clearance Rate; Myoglobin; Myoglobinuria; Pyridines; Rhabdomyolysis; Simvastatin; Time Factors

2005

Myoglobinuria and COX deficiency in a patient taking cerivastatin and gemfibrozil.

Neurology, 2003, Jan-14, Volume: 60, Issue:1

The authors describe a patient who presented with myoglobinuria after starting cerivastatin-gemfibrozil therapy. Muscle histochemistry revealed ragged-red fibers and cytochrome c oxidase negative (COX) fibers, and biochemistry showed a defect of COX activity. Immunoblot analysis showed a 60% reduction of COX I and COX II polypeptides. Cerivastatin myotoxicity might be related to a depletion of essential metabolites needed to anchor COX subunit I to mitochondrial membrane.

Topics: Aged; Biopsy; Cytochrome-c Oxidase Deficiency; Female; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Muscle Fibers, Fast-Twitch; Muscle Weakness; Muscle, Skeletal; Myoglobinuria; Pain; Pyridines

2003